Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. UK Medicines and Healthcare Products Regulatory Agency. Evusheld approved to prevent COVID-19 in people whose immune response is poor [media release]. 17 Mar 2022. https://www.gov.uk/government/news/.
2. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2116620.
3. European Medicines Agency. Evusheld: EPAR—assessment report. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/evusheld. Accessed 4 May 2022.
4. Boggiano CP, Eisinger RWP, Lerner AMMD, et al. Update on and future directions for use of anti-SARS-CoV-2 antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19. Ann Intern Med. 2022;175(1):119–26.
5. AstraZeneca. Advancing our discovery of novel coronavirus-neutralising antibodies against COVID-19 [media release]. 9 June 2020. http://www.astrazeneca.com.
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献